SCHEMBL5865640

SCHEMBL5865640

FC(F)(F)c1cc(C(=C(Cl)Cl)c2ccc(Br)cc2)ccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPFFR2 Q9Y5X5 1/20 0.44
KDR P35968 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40
HTR3A P46098 1/20 0.40
HTR3D Q70Z44 1/20 0.40
HTR3C Q8WXA8 1/20 0.40
PDK1 Q15118 1/20 0.39
HSD11B1 P28845 1/20 0.39
MEP1B Q16820 1/20 0.37
SLC6A3 Q01959 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5865501 0.88 CYP3A4 (0.40) KDRLMNATP53MAPTTHRB
SCHEMBL5865578 0.87 MAPT (0.46) LMNAMAPTCYP3A4TSHRMAPK1
SCHEMBL5865560 0.87 CYP3A4 (0.57) NPFFR2KDRLMNATP53MAPT
SCHEMBL5865631 0.83 NOTUM (0.53) LMNAMAPTCYP3A4TSHRMAPK1
SCHEMBL5865199 0.79 CYP3A4 (0.55) LMNAMAPTCYP3A4TSHRMAPK1
SCHEMBL1794695 0.76 KDR (0.54) NPFFR2KDRLMNAMAPTHTR3E
SCHEMBL31542016 0.76 KDR (0.54) NPFFR2KDRLMNAMAPTHTR3E
SCHEMBL264729 0.75 IDO1 (0.47) NPFFR2KDRLMNATP53MAPT
SCHEMBL29707579 0.75 IDO1 (0.47) NPFFR2KDRLMNATP53MAPT
SCHEMBL9494805 0.75 TSHR (0.59) LMNAMAPTCYP3A4TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7091248-B2 Treatment of adrenocortical hypersecretion and tumor growth BRANDT INGVAR 2006-08-15 US disclosed
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth BRANDT INGVAR (SE) 2004-12-02 US disclosed
EP-1412311-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH Brandt, Ingvar (SE) 2004-04-28 EP disclosed
WO-2003002495-A1 NOVEL TREATMENT OF ADRENOCORTICAL HYPERSECRETION AND TUMOUR GROWTH BRANDT INGVAR (SE) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242705-A1 Novel treatment of adrenocortical hypersecretion and tumour growth NR3C2, NR5A1, NR3C1 NPFFR2 332/4885KDR 295/4885LMNA 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.